Navigation Links
UR discovers new way to boost vaccines, seeks patent
Date:8/4/2010

As the medical community searches for better vaccines and ways to deliver them, a University of Rochester scientist believes he has discovered a new approach to boosting the body's response to vaccinations.

Richard P. Phipps, Ph.D., found that the same molecules used in drugs that treat diabetes also stimulate B cells in the immune system, pushing them to make antibodies for protection against invading microorganisms.

The University of Rochester Medical Center has applied for international patent protection for this discovery.

Phipps believes further research will show that low doses of insulin-sensitizing drugs might be useful as vaccine adjuvants, particularly for people with weakened immune systems who cannot produce a proper antibody response. This would include some infants, the elderly, and patients with chronic health problems that lower immunity.

Currently the only widely approved vaccine adjuvant in the United States is alum. A vaccine adjuvant is a substance added to a vaccine to improve the body's immune response. Various forms of aluminum salts have been used for 70 years. (Adjuvants are added to some vaccines but not all. For example, live viral vaccines given during childhood and seasonal flu vaccines do not contain adjuvants.)

"The search is always on for new adjuvants and safe adjuvants," said Phipps, a Dean's Professor of Environmental Medicine and professor of Medicine, Oncology, Ophthalmology, Microbology and Immunology, Pediatrics and Pathology and Laboratory Medicine. "We are excited that we've identified a potentially important new and effective adjuvant."

Phipps' discovery grew from years of NIH-funded research investigating a protein called PPAR gamma and its ligands, which are present inside B cells and are involved in inflammation and in regulating the properties of immune cells and cancer cells. The way B cells evolve, or differentiate, is central to the body's immune response.

A closer examination of the role of PPAR gamma in relation to B cell function showed that PPAR levels increase upon B cell activation, according to a study published in 2009 by Phipps' laboratory in the Journal of Immunology.

Thus, researchers theorized that any molecule that binds to and activates PPAR gamma would, in turn, improve B cell secretion of antibodies. Researchers tested both natural and synthetic PPAR gamma ligands and discovered that the synthetic molecules used to create anti-diabetic drugs such as Actos and Avandia stimulated human and mouse B cells to better produce antibodies.

The drawback, Phipps said, is the possibility that too much stimulation would cause the immune system to overreact, triggering autoimmune diseases such as rheumatoid arthritis or lupus. Additional research is needed to better understand this process.


'/>"/>

Contact: Leslie Orr
Leslie_Orr@urmc.rochester.edu
585-275-5774
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses
2. Professional Web Design Agency Discovers Winning Web Development Formula for Beating the Recession.
3. 28-Year Old from Texas Discovers His Own 'Instant Weight-Loss' Miracle Online
4. IU research team discovers TB disease mechanism and molecule to block it
5. High Cholesterol in Youth Boosts Heart Risk In Middle Age
6. Boosting the efficacy of anticancer vaccines
7. Calcium Supplements Linked to Boost in Heart Attack Risk
8. Vaccine Boosts Survival for Men With Advanced Prostate Cancer: Study
9. Radiation for Childhood Cancer Can Boost Risk of Stillbirth Later
10. Some on Statins May Not Need Boost in Good Cholesterol
11. NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of sub-acute ... of a disaster drill on October 3rd. , Apple Rehab participated with the Shelton ... well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The LTC-MAP ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
Breaking Medicine Technology: